Curis, Inc. (CRIS) stock forecast & analysis
0.8714
NasdaqCM · USDDelayed by 15 minutes
Down: -0.2386, -21.5%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.9848
- Previous close
- 1.11
- Day range
- 0.8500 – 1.09
- 52-week range
- 0.3300 – 29.80
- Volume (shares)
- 11.23M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 6.68M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 3.25
- Market cap
- 5.82M
Market Scanner’s AI analysis of Curis, Inc. (CRIS), updated November 2026: Curis, Inc. (CRIS) surge driven by reverse stock split vote and clinical data anticipation, alongside a private placement.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Curis, Inc. (CRIS) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Curis, Inc. (CRIS) surge driven by reverse stock split vote and clinical data anticipation, alongside a private placement.
Recent analyses for Curis, Inc. (CRIS) covered a significant price surge attributed to a reverse stock split vote and anticipation of clinical data releases. The company also announced an $8.5 million private placement. Financials indicate a decline in trailing twelve months revenue compared to prior years, with mixed quarterly net income results.
CRIS news & sentiment
News reports highlighted a significant surge in Curis, Inc. (CRIS) driven by a reverse stock split vote and anticipation of clinical data, alongside a private placement announcement. Market analysis also positioned the company within the VISTA inhibitor landscape.
CRIS technical picture
CRIS saw a strong short-term upward trend with the price above the 10-day EMA, but remained below the 50-day and 200-day SMAs, indicating bearish medium and long-term trends. Momentum readings were mixed, with RSI in overbought territory and MFI showing strong buying pressure, while MACD indicated bearish momentum despite an upward trend.
Fundamentals
Annual revenue declined from 2024 to 2025, with mixed quarterly net income results. The company has a negative forward P/E ratio and reported a net loss for the quarter ending March 31, 2026.
Factors discussed — upside
- Strong 7-day price change of +146.7%
- Current price above 10-day EMA
- High Money Flow Index (MFI) at 99.70
- Anticipation of upcoming clinical data releases
- Announcement of an $8.5 million private placement
Factors discussed — risks
- Significant 91-day price decline of -75.6%
- Current price below 50-day SMA and 200-day SMA
- RSI above overbought threshold of 70
- Declining annual revenue from 2024 to 2025
- Negative operating and net income in Q1 2026
- Market trends
- Financial performance
- Clinical data
- Corporate financing
Summary updated .
CRIS technical indicators
Common technical indicators for CRIS, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.86 | Price above |
| 10-day exponential moving average | 0.70 | Price above |
| Relative strength index (14-day) | 56.85 | Neutral |
| MACD line (12/26/9) | -0.0408 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.18 – 0.93 | Price inside the bands |
Analyses
Recent CRIS.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-05 CRIS.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Curis, Inc.?
- Recent analyses highlighted a strong short-term upward price trend, evidenced by a significant 7-day price change and the current price trading above its 10-day exponential moving average. Investor attention has been drawn by anticipation of upcoming clinical data releases and the announcement of an $8.5 million private placement.
- What are the risks for Curis, Inc.?
- The company's medium and long-term trends remain bearish, with the current stock price trading below its 50-day and 200-day simple moving averages, despite a significant recent surge. The Relative Strength Index (RSI) is above the overbought threshold, suggesting the recent price action may not be sustainable, and annual revenue has shown a declining trend over the past few years.
- Is Curis, Inc. bullish or bearish?
- Recent AI analyses of Curis, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted a strong short-term upward price trend, evidenced by a significant 7-day price change and the current price trading above its 10-day exponential moving average. Investor attention has been drawn by anticipation of upcoming clinical data releases and the announcement of an $8.5 million private placement. Discussed risks: The company's medium and long-term trends remain bearish, with the current stock price trading below its 50-day and 200-day simple moving averages, despite a significant recent surge. The Relative Strength Index (RSI) is above the overbought threshold, suggesting the recent price action may not be sustainable, and annual revenue has shown a declining trend over the past few years. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Curis, Inc.?
- News reports highlighted a significant surge in Curis, Inc. (CRIS) driven by a reverse stock split vote and anticipation of clinical data, alongside a private placement announcement. Market analysis also positioned the company within the VISTA inhibitor landscape.
- How does Market Scanner analyse Curis, Inc.?
- Every analysis of Curis, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Curis, Inc.?
Recent analyses highlighted a strong short-term upward price trend, evidenced by a significant 7-day price change and the current price trading above its 10-day exponential moving average. Investor attention has been drawn by anticipation of upcoming clinical data releases and the announcement of an $8.5 million private placement.
What are the risks for Curis, Inc.?
The company's medium and long-term trends remain bearish, with the current stock price trading below its 50-day and 200-day simple moving averages, despite a significant recent surge. The Relative Strength Index (RSI) is above the overbought threshold, suggesting the recent price action may not be sustainable, and annual revenue has shown a declining trend over the past few years.
Is Curis, Inc. bullish or bearish?
Recent AI analyses of Curis, Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted a strong short-term upward price trend, evidenced by a significant 7-day price change and the current price trading above its 10-day exponential moving average. Investor attention has been drawn by anticipation of upcoming clinical data releases and the announcement of an $8.5 million private placement. Discussed risks: The company's medium and long-term trends remain bearish, with the current stock price trading below its 50-day and 200-day simple moving averages, despite a significant recent surge. The Relative Strength Index (RSI) is above the overbought threshold, suggesting the recent price action may not be sustainable, and annual revenue has shown a declining trend over the past few years. These are descriptive observations, not a recommendation.
What is the latest sentiment on Curis, Inc.?
News reports highlighted a significant surge in Curis, Inc. (CRIS) driven by a reverse stock split vote and anticipation of clinical data, alongside a private placement announcement. Market analysis also positioned the company within the VISTA inhibitor landscape.
How does Market Scanner analyse Curis, Inc.?
Every analysis of Curis, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh CRIS.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.